- Home
- OGEN vs PRTG Comparison
OGEN vs PRTG Comparison
Compare OGEN & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- PRTG
- Stock Information
- Founded
- OGEN 1996
- PRTG 1973
- Country
- OGEN United States
- PRTG British Virgin Islands
- Employees
- OGEN N/A
- PRTG N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- PRTG Oil & Gas Production
- Sector
- OGEN Health Care
- PRTG Energy
- Exchange
- OGEN Nasdaq
- PRTG Nasdaq
- Market Cap
- OGEN 4.5M
- PRTG 5.3M
- IPO Year
- OGEN N/A
- PRTG N/A
- Fundamental
- Price
- OGEN $0.32
- PRTG $4.09
- Analyst Decision
- OGEN
- PRTG Hold
- Analyst Count
- OGEN 0
- PRTG 1
- Target Price
- OGEN N/A
- PRTG N/A
- AVG Volume (30 Days)
- OGEN 738.8K
- PRTG 51.9K
- Earning Date
- OGEN 11-13-2024
- PRTG 11-26-2024
- Dividend Yield
- OGEN N/A
- PRTG N/A
- EPS Growth
- OGEN N/A
- PRTG N/A
- EPS
- OGEN N/A
- PRTG N/A
- Revenue
- OGEN N/A
- PRTG N/A
- Revenue This Year
- OGEN N/A
- PRTG N/A
- Revenue Next Year
- OGEN N/A
- PRTG N/A
- P/E Ratio
- OGEN N/A
- PRTG N/A
- Revenue Growth
- OGEN N/A
- PRTG N/A
- 52 Week Low
- OGEN $0.28
- PRTG $2.10
- 52 Week High
- OGEN $7.74
- PRTG $40.80
- Technical
- Relative Strength Index (RSI)
- OGEN 41.16
- PRTG 35.81
- Support Level
- OGEN $0.30
- PRTG $3.80
- Resistance Level
- OGEN $0.43
- PRTG $4.49
- Average True Range (ATR)
- OGEN 0.03
- PRTG 0.53
- MACD
- OGEN 0.01
- PRTG -0.15
- Stochastic Oscillator
- OGEN 23.47
- PRTG 12.12
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.